Second generation direct-acting antivirals – Do we expect major improvements?  Jordan J. Feld, Graham R. Foster  Journal of Hepatology  Volume 65, Issue 1, Pages S130-S142 (October 2016) DOI: 10.1016/j.jhep.2016.07.007 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 The challenge of G3 cirrhosis. SVR rates are shown with currently and soon-to-be approved regimens for patients with genotype 3 and cirrhosis. Although encouraging progress has been made, results for this sub-group of patients remain suboptimal compared to other populations. Journal of Hepatology 2016 65, S130-S142DOI: (10.1016/j.jhep.2016.07.007) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Schematic representation of DAA development in order to reach global HCV elimination. The vast majority of patients who receive all oral DAA therapy will achieve sustained virological response (green). However, a second generation of drugs will address the unresolved issues for patients where current treatments are still not satisfactory (red; blue bubbles). Refinement of drug delivery approaches will be necessary to achieve ‘cure-all’ treatments. Journal of Hepatology 2016 65, S130-S142DOI: (10.1016/j.jhep.2016.07.007) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions